Last reviewed · How we verify
A Prospective, Randomised, Investigator-Blinded, Vehicle-Controlled, Phase I Clinical Trial With Intra-Individual Comparison of Treatments to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin
The purpose of this study is to assess the effect of LEO 130852A gel 1% in maintaining skin thickness in healthy skin treated with steroid.
Details
| Lead sponsor | LEO Pharma |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 40 |
| Start date | 2015-03 |
| Completion | 2015-06 |
Conditions
- Skin Tissue Diseases
- Connective Tissue Diseases
Interventions
- Clobetasol propionate 0.05% ointment
- LEO 130852A gel 1%
- LEO 130852A placebo gel
Primary outcomes
- Skin thickness measured by sonography and histology — 4 weeks
Countries
Germany